MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 531170 | Name: GTPL5846
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

GTPL5846 increases chemotaxis of polymorphonuclear leukocytes and macrophages and stimulates production of pro-inflammatory cytokines.

Chemical Structure

GTPL5846
GTPL5846
CAS#83797-69-7

Theoretical Analysis

MedKoo Cat#: 531170

Name: GTPL5846

CAS#: 83797-69-7

Chemical Formula: C12H21N3O2

Exact Mass: 239.1634

Molecular Weight: 239.32

Elemental Analysis: C, 60.23; H, 8.85; N, 17.56; O, 13.37

Price and Availability

Size Price Availability Quantity
100mg USD 750.00 2 Weeks
200mg USD 1,250.00 2 Weeks
500mg USD 2,650.00 2 Weeks
1g USD 4,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
GTPL5846; GTPL 5846; GTPL-5846; 6-OAU; 6-n-octylaminouracil
IUPAC/Chemical Name
6-(Octylamino)-2,4(1H,3H)-pyrimidinedione
InChi Key
PFSWASUQURIOOR-UHFFFAOYSA-N
InChi Code
InChI=1S/C12H21N3O2/c1-2-3-4-5-6-7-8-13-10-9-11(16)15-12(17)14-10/h9H,2-8H2,1H3,(H3,13,14,15,16,17)
SMILES Code
O=C1NC(C=C(NCCCCCCCC)N1)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
6-OAU (GTPL5846) (6-n-octylaminouracil) is an GPR84 (G protein-coupled receptor 84) agonist, with an EC50 value of 105 nM.
In vitro activity:
Rather, 6-OAU significantly suppressed mRNA expression of IL-6 (1 μM, p = 0.019) and IL-12 p40 (0.1 μM, p = 0.02) (Fig. 1a). Reference: J Neuroinflammation. 2017 Oct 3;14(1):198. https://pubmed.ncbi.nlm.nih.gov/28974234/
In vivo activity:
The in vivo studies showed that both treatments via oral route augmented resistance to Brucella infection but more pronounced with 6-OAU as observed with reduced bacterial proliferation in spleens and livers. At 7 d post-treatment and 14 d post-infection, 6-OAU-treated mice displayed reduced IFN-γ serum level. Reference: Microb Pathog. 2021 Sep;158:105079. https://pubmed.ncbi.nlm.nih.gov/34245824/
Solvent mg/mL mM
Solubility
DMSO 30.0 125.36
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 239.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Wei L, Tokizane K, Konishi H, Yu HR, Kiyama H. Agonists for G-protein-coupled receptor 84 (GPR84) alter cellular morphology and motility but do not induce pro-inflammatory responses in microglia. J Neuroinflammation. 2017 Oct 3;14(1):198. doi: 10.1186/s12974-017-0970-y. PMID: 28974234; PMCID: PMC5627487. 2. Suzuki M, Takaishi S, Nagasaki M, Onozawa Y, Iino I, Maeda H, Komai T, Oda T. Medium-chain fatty acid-sensing receptor, GPR84, is a proinflammatory receptor. J Biol Chem. 2013 Apr 12;288(15):10684-91. doi: 10.1074/jbc.M112.420042. Epub 2013 Feb 28. PMID: 23449982; PMCID: PMC3624448. 3. Reyes AWB, Kim H, Huy TXN, Vu SH, Nguyen TT, Kang CK, Min W, Lee HJ, Lee JH, Kim S. Immune-metabolic receptor GPR84 surrogate and endogenous agonists, 6-OAU and lauric acid, alter Brucella abortus 544 infection in both in vitro and in vivo systems. Microb Pathog. 2021 Sep;158:105079. doi: 10.1016/j.micpath.2021.105079. Epub 2021 Jul 8. PMID: 34245824.
In vitro protocol:
1. Wei L, Tokizane K, Konishi H, Yu HR, Kiyama H. Agonists for G-protein-coupled receptor 84 (GPR84) alter cellular morphology and motility but do not induce pro-inflammatory responses in microglia. J Neuroinflammation. 2017 Oct 3;14(1):198. doi: 10.1186/s12974-017-0970-y. PMID: 28974234; PMCID: PMC5627487. 2. Suzuki M, Takaishi S, Nagasaki M, Onozawa Y, Iino I, Maeda H, Komai T, Oda T. Medium-chain fatty acid-sensing receptor, GPR84, is a proinflammatory receptor. J Biol Chem. 2013 Apr 12;288(15):10684-91. doi: 10.1074/jbc.M112.420042. Epub 2013 Feb 28. PMID: 23449982; PMCID: PMC3624448.
In vivo protocol:
1. Reyes AWB, Kim H, Huy TXN, Vu SH, Nguyen TT, Kang CK, Min W, Lee HJ, Lee JH, Kim S. Immune-metabolic receptor GPR84 surrogate and endogenous agonists, 6-OAU and lauric acid, alter Brucella abortus 544 infection in both in vitro and in vivo systems. Microb Pathog. 2021 Sep;158:105079. doi: 10.1016/j.micpath.2021.105079. Epub 2021 Jul 8. PMID: 34245824.
1: Sun XN, An YA, Paschoal VA, de Souza CO, Wang MY, Vishvanath L, Bueno LM, Cobb AS, Nieto Carrion JA, Ibe ME, Li C, Kidd HA, Chen S, Li W, Gupta RK, Oh DY. GPR84-mediated signal transduction affects metabolic function by promoting brown adipocyte activity. J Clin Invest. 2023 Dec 15;133(24):e168992. doi: 10.1172/JCI168992. PMID: 37856216; PMCID: PMC10721148. 2: Zhang X, Wang Y, Supekar S, Cao X, Zhou J, Dang J, Chen S, Jenkins L, Marsango S, Li X, Liu G, Milligan G, Feng M, Fan H, Gong W, Zhang C. Pro- phagocytic function and structural basis of GPR84 signaling. Nat Commun. 2023 Sep 14;14(1):5706. doi: 10.1038/s41467-023-41201-0. PMID: 37709767; PMCID: PMC10502086. 3: Reyes AWB, Kim H, Huy TXN, Vu SH, Nguyen TT, Kang CK, Min W, Lee HJ, Lee JH, Kim S. Immune-metabolic receptor GPR84 surrogate and endogenous agonists, 6-OAU and lauric acid, alter Brucella abortus 544 infection in both in vitro and in vivo systems. Microb Pathog. 2021 Sep;158:105079. doi: 10.1016/j.micpath.2021.105079. Epub 2021 Jul 8. PMID: 34245824. 4: Li J, Ma A, Zhang R, Chen Y, Bolyard C, Zhao B, Wang C, Pich T, Li W, Sun N, Ma Q, Wen H, Clinton SK, Carson WE 3rd, Li Z, Xin G. Targeting metabolic sensing switch GPR84 on macrophages for cancer immunotherapy. Cancer Immunol Immunother. 2024 Feb 13;73(3):52. doi: 10.1007/s00262-023-03603-3. PMID: 38349405; PMCID: PMC10864225. 5: Zhang X, Wang Y, Supekar S, Cao X, Zhou J, Dang J, Chen S, Jenkins L, Marsango S, Li X, Liu G, Milligan G, Feng M, Fan H, Gong W, Zhang C. Pro- phagocytic function and structural basis of GPR84 signaling. Res Sq [Preprint]. 2023 Feb 15:rs.3.rs-2535247. doi: 10.21203/rs.3.rs-2535247/v1. Update in: Nat Commun. 2023 Sep 14;14(1):5706. doi: 10.1038/s41467-023-41201-0. PMID: 36824923; PMCID: PMC9949259. 6: Suzuki M, Takaishi S, Nagasaki M, Onozawa Y, Iino I, Maeda H, Komai T, Oda T. Medium-chain fatty acid-sensing receptor, GPR84, is a proinflammatory receptor. J Biol Chem. 2013 Apr 12;288(15):10684-91. doi: 10.1074/jbc.M112.420042. Epub 2013 Feb 28. PMID: 23449982; PMCID: PMC3624448. 7: Luscombe VB, Baena-López LA, Bataille CJR, Russell AJ, Greaves DR. Kinetic insights into agonist-dependent signalling bias at the pro-inflammatory G-protein coupled receptor GPR84. Eur J Pharmacol. 2023 Oct 5;956:175960. doi: 10.1016/j.ejphar.2023.175960. Epub 2023 Aug 3. PMID: 37543157; PMCID: PMC10804997. 8: Wei L, Tokizane K, Konishi H, Yu HR, Kiyama H. Agonists for G-protein-coupled receptor 84 (GPR84) alter cellular morphology and motility but do not induce pro-inflammatory responses in microglia. J Neuroinflammation. 2017 Oct 3;14(1):198. doi: 10.1186/s12974-017-0970-y. PMID: 28974234; PMCID: PMC5627487. 9: Recio C, Lucy D, Purvis GSD, Iveson P, Zeboudj L, Iqbal AJ, Lin D, O'Callaghan C, Davison L, Griesbach E, Russell AJ, Wynne GM, Dib L, Monaco C, Greaves DR. Activation of the Immune-Metabolic Receptor GPR84 Enhances Inflammation and Phagocytosis in Macrophages. Front Immunol. 2018 Jun 20;9:1419. doi: 10.3389/fimmu.2018.01419. PMID: 29973940; PMCID: PMC6019444. 10: Marsango S, Ward RJ, Jenkins L, Butcher AJ, Al Mahmud Z, Dwomoh L, Nagel F, Schulz S, Tikhonova IG, Tobin AB, Milligan G. Selective phosphorylation of threonine residues defines GPR84-arrestin interactions of biased ligands. J Biol Chem. 2022 May;298(5):101932. doi: 10.1016/j.jbc.2022.101932. Epub 2022 Apr 12. PMID: 35427647; PMCID: PMC9118924.